The paradigmatic example of clinical relevance of TP53 mutations in MDS is provided by MDS with del(5q): subclones carrying TP53-mutations may occur at an early disease stage in MDS with del(5q) and are closely associated with a poor response to lenalidomide and with an increased risk of leukemic evolution [37]. The gene discussed is TP53; the disease is myelodysplastic syndrome.